Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.66 |
| ▸ | HTR1A | P08908 | 8/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | JUND | P17535 | 1/20 | 0.47 |
| ▸ | FOSB | P53539 | 1/20 | 0.47 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020016 | 0.88 | HTR1A (0.70) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4888805 | 0.87 | HTR1A (0.68) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9870482 | 0.86 | ABCB1 (0.64) | HTR2CHTR1AABCB1 | |
| SCHEMBL19072578 | 0.80 | ABCB1 (0.68) | HTR2CABCB1 | |
| SCHEMBL330081 | 0.79 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29891667 | 0.79 | HTR2C (1.00) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5585144 | 0.79 | HTR2C (0.51) | HTR2CHTR1ASLC6A2SLC6A4JUND | |
| SCHEMBL5584542 | 0.79 | HTR2C (0.73) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25044018 | 0.79 | HTR1A (0.58) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6795747 | 0.79 | HTR2C (0.54) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| CN-102295636-A | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | — | 2011-12-28 | — | — | CN | disclosed |
| US-8076360-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-2102186-B1 | INDOLES | HOFFMANN LA ROCHE (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-8026259-B2 | e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | disclosed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101547914-A | Indoles compound | HOFFMANN LA ROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| EP-2102186-A1 | INDOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| CN-1316994-A | Piperidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-10 | — | — | CN | disclosed |
| EP-1109786-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014067-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | HTR2C 30/4885HTR1A 16/4885SLC6A2 2254/4885 |
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR1A 1/4885SLC6A2 21/4885 |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | HTR2C 30/4885HTR1A 16/4885SLC6A2 2254/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | HTR2C 30/4885HTR1A 16/4885SLC6A2 2254/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR1A 1/4885SLC6A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.